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Abstract: Human T-cell Lymphotropic Virus type 1 (HTLV-1) is a human retrovirus that infects at
least 5–10 million people worldwide, and is the etiological agent of a lymphoproliferative malignancy;
Adult T-cell Leukemia/Lymphoma (ATLL); and a chronic neuromyelopathy, HTLV-1 Associated
Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), as well as other inflammatory diseases
such as infective dermatitis and uveitis. Besides sexual intercourse and intravenous transmission,
HTLV-1 can also be transmitted from infected mother to child during prolonged breastfeeding. Some
characteristics that are linked to mother-to-child transmission (MTCT) of HTLV-1, such as the role
of proviral load, antibody titer of the infected mother, and duration of breastfeeding, have been
elucidated; however, most of the mechanisms underlying HTLV-1 transmission during breast feeding
remain largely unknown, such as the sites of infection and cellular targets as well as the role of milk
factors. The present review focuses on the latest findings and current opinions and perspectives on
MTCT of HTLV-1.
Keywords: human; HTLV-1; intestinal barrier; retrovirus; breastfeeding
1. Introduction
Human T-cell Leukemia Virus Type 1 (HTLV-1) infects at least 5–10 million people worldwide,
mainly in highly endemic areas such as southern Japan, West/Central Africa, the Caribbean region,
and parts of South America and Melanesia [1]. HTLV-1 infection is mostly associated with two distinct
diseases: a lymphoproliferation, Adult T cell Leukemia/Lymphoma (ATLL), and an inflammatory
neurological disease, tropical spastic paraparesis or HTLV-1 associated myelopathy (HAM/TSP).
Additionally, HTLV-1 is associated with other inflammatory diseases such as infective dermatitis, some
uveitis and some myositis. Although HTLV-1 preferentially infects CD4+ T cells [2], CD8+ T-cells
may play an important role as reservoir in the host [3], and to a lesser extent, infected monocytes
and B lymphocytes, dendritic cells, and endothelial cells may be found [4,5]. Different modes of
transmission have been identified for HTLV-1: (1) sexual contact; (2) transfusion of contaminated
blood; and (3) from mother to child (MTCT) [6]. In each case, such a transmission involves the transfer
of infected body fluid (semen, blood, and milk, respectively). In the case of MTCT, cohort studies
on HTLV-1 infected carriers indicate that infection during childhood is a potent risk factor for the
development of ATLL [7]. It is now clear that HTLV-1 MTCT mainly involves prolonged breastfeeding,
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as demonstrated by epidemiological, virological and experimental data. However, the mechanisms of
such a transmission remain largely unknown. For instance, the nature of the infected cells present in
the milk, the anatomical sites of viral entry through the mucosa, the first cellular targets of infection,
the role of anti-HTLV-1 antibodies present in breast milk, and the role of other milk factors that may
influence MTCT have not been completely addressed. The present review focuses on such mechanisms,
current studies and perspectives.
2. Evidence of HTLV-1 MTCT during Breastfeeding
First evidence of HTLV-1 transmission from infected mother to children during lactation has been
brought by epidemiological studies. HTLV-1 infection was more prevalent among breastfed children
than bottle-fed children in Japan [8,9], with a rate of seroconversion of 15.7% among children that
had been breastfed for 12 months, compared to 3.6% for bottle-fed children for similar period [10].
Moreover, there is a correlation between MTCT rate and breastfeeding duration. Thus, in a prospective
study in Jamaica, Wiktor et al. [11] reported that breastfeeding beyond 12 months was associated with
a transmission rate of 32%, compared to a transmission rate of 9% for shorter breastfeeding durations.
Similarly, Takahashi et al. [12] showed that a six-month duration of breastfeeding was a critical point in
the rate of seroconversion, since rates of 4.4% and 14.4% were found for children that had been breastfed
for periods under six months or over seven months, respectively. A major piece of evidence supporting
HTLV-1 transmission through breastfeeding has been brought in the 1980s in Japan, where Hino and
coworkers started a pilot study to screen pregnant women in Nagasaki Prefecture for anti-HTLV-1
antibodies (for a review, see [13]). HTLV-1 prevalence was around 4%. Interestingly, HTLV-1 prevalence
among the elder children of the HTLV-1 carrier mothers was approximately 20%, and mothers of the
HTLV-1 positive children were usually HTLV-1 positive (92%), thus showing evidence of MTCT. More
importantly, in 1987, the ATLL Prevention Program Nagasaki, which aimed to refrain seropositive
mothers from breastfeeding in the Nagasaki Prefecture, resulted in a huge reduction of HTLV-1 MTCT
from 20.3% to 2.5% [14]. The major importance of breastfeeding in HTLV-1 MTCT was later confirmed
in other areas [15]. Of note, this residual rate (2.5%) of MTCT in the absence of breastfeeding raised
the possibility of minor secondary routes, such as contamination during delivery, or intrauterine
transmission. This latter route remains controversial, since contradictory studies on the presence of
HTLV-1 in cord-blood samples from seropositive babies have been reported [16–18].
From a virological point of view, it is known that many retroviruses may be transmitted via
breast milk, such as Moloney murine leukemia virus [19,20], Mouse Mammary Tumor Virus [21], or
Caprine Arthritis Encephalitis Virus [22]. Concerning HTLV-1, viral antigens [23], and antibodies
to HTLV-1 were found in the milk of seropositive mothers [24]. The proviral load in breast milk is
strongly predictive of the risk of MTCT, increasing from 4.7/1000 person-months for a provirus load in
milk lower than 0.18% to 28.7/1000 person-months for a provirus load higher than 1.5% [25].
From an experimental point of view, oral inoculation of peripheral blood lymphocytes isolated
from ATLL patients to adult common marmosets (Callithrix jacus) was able to induce seroconversion
within 2.5 months, and the virus was detected in the animal peripheral blood lymphocytes [26].
This study also demonstrated that 5.6 ˆ 107 cells from ATLL patients were sufficient to infect these
animals. Similarly, oral inoculation of concentrated fresh milk from HTLV-1 seropositive mothers
in the same animal model could transmit the infection [27]. Oral transmission of HTLV-1 could be
likewise observed in other animal models. Oral inoculation of four rabbits for eight weeks with an
HTLV-1-infected rabbit lymphoid cell line resulted in the seroconversion of one animal, and it was
possible to generate from this animal a lymphoid cell line productively infected with HTLV-1 [28].
Similarly, oral inoculation of HTLV-1-infected lymphoid cell line (i.e., MT-2) to rats induced a persistent
HTLV-1 infection in the absence of both humoral and cellular immune responses [29].
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3. The Mechanisms of HTLV-1 MTCT
Altogether, these data indicate that breastfeeding is a major route for HTLV-1 MTCT. However,
the mechanisms of HTLV-1 passage through the digestive tract remain largely unknown.
A first point to address concerns the source of HTLV-1 infection in breast milk. It is known that
cell-to-cell contact is required for efficient viral transmission in vivo [30] as well as in vitro [31,32], except
for dendritic cells that can be infected directly with cell-free HTLV-1 virions [33]. Cell free virions have
not been detected so far in breast milk, thus the potential source of infection in breast milk may come
from infected cells, such as lymphocytes, macrophages, or breast epithelial mammary cells. Since
it has been estimated that breastfed children ingest an average of 108 leucocytes a day, considering
prolonged breastfeeding [34,35], infected lymphocytes could provide a strong source of infection in
milk [36]. HTLV-1 infected mononuclear cells can be found in the milk from seropositive mothers
during early lactation [23,37]. Of note, cellular components in breast milk can be found even after
long-term lactation (over 5 years) [38], even if the ratio between the different cell types varies along
the time: for example, the major part of cells in mother’s early milk and colostrum is constituted of
macrophages [39]. It has been found that leukocytes and epithelial cells from the mammary gland are
susceptible to HTLV-1 infection [38]. This observation was confirmed by the evidence that mammary
basal epithelial cells can be productively infected with HTLV-1 and are able to transfer infection to
peripheral blood lymphocytes [40,41]. In addition, in a case report of an ATLL male patient with
pseudogynecomasty, breast biopsy revealed the presence of mammary epithelial cells productively
infected with HTLV-1 [42]. Such data support the hypothesis that basal and/or luminal epithelial
cells may constitute a reservoir of HTLV-1 infectivity. The importance of mammary epithelial cells in
viral transmission during lactation has also been evoked for Bovine Leukemia Virus (BLV), another
deltaretrovirus that is transmitted from BLV-infected cows to calves during lactation [43]. Whatever
the cell types involved, this can provide a more or less continuous source of infection.
A second question concerning the mechanisms of HTLV-1 transmission through the digestive
tract is the anatomical site of viral entry. Up until now, no studies have addressed this question; in fact,
animal models studies (marmoset, rabbit, and rat) on oral inoculation of HTLV-1 were mainly focused
on seroconversion, progression towards an ATLL-like disease, and immune status of the host. Among
the different possible sites of entry, the palatine tonsils and gut seem to be of particular importance
due to their enrichment in possible targets (lymphoid cells and M cells), their function in antigen
sampling [44] and their structure. Moreover, although it does not constitute a proof of viral entry,
HTLV-1 may be retrieved in these structures, as shown in the tonsils for HTLV-1 infected humans [45],
in the intestine and mesenteric lymph nodes of squirrel monkeys inoculated intravenously with
HTLV-1 [46] and in Gut-Associated-Lymphoid Tissues from orally inoculated rabbits [47]. Whatever
the primary sites of HTLV-1 passage/infection, tonsils and/or gut, the virus encounters an epithelium,
pluristratified or monostratified, respectively. This allows in vitro studies using classical models of
human epithelial cell monolayers.
Very few in vitro studies have been published concerning the mechanisms of passage of HTLV-1
across the intestinal barrier. In 1992, Zacharopoulos et al. [48] indicated that a human enterocytic
cell lines (i.e., I407) was susceptible to HTLV-1 infection in vitro, as shown by electron microscopy,
in situ hybridization, and PCR amplification. However, it was unclear if the cells were fully
differentiated as no data on the epithelium integrity and tight junctions were shown. In contrast, our
laboratory performed studies on the susceptibility of three different human enterocytic cell lines on
compartmentalized culture devices, with assessment of the enterocyte differentiation: existence of
a tight epithelial barrier was checked by electron and confocal microscopy, and the trans-epithelial
resistance was measured [49]. In this study, as summarized in Figure 1, it was demonstrated that
HTLV-1 infected lymphocytes were unable to disrupt the epithelial barrier integrity or infect human
enterocytes, in contrast to previous studies on a blood–brain barrier model in human brain endothelial
cells [5,50]. However, it was shown that HTLV-1 virions were able to cross the epithelial barrier by
transcytosis mechanism, and productively infect underlying human dendritic cells [49].
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cells and B lymphocytes) are located. From in vitro studies [49], the infection of enterocytes or the 
epithelial layer disruption seems to be excluded. Another possibility, suggested in the same study, 
could be viral transcytosis through the enterocyte, with infection of underlying dendritic cells. 
Interestingly, viral transcytosis through enterocytes was observed only in the presence of HTLV-
1 infected lymphocytes, and not in the case of purified virions. Such a mechanism of viral transcytosis 
is reminiscent of previous work showing transcytosis of HIV across an epithelial barrier, without 
infection of enterocytes, and subsequent infection of macrophages or CD4 lymphocytes located to the 
basal side of the epithelium [51]. These in vitro results highlight one of the potential mechanisms 
proposed for HTLV-1 passage, which are summarized in Figure 1. 
4. Determinants of HTLV-1 MTCT 
Studies on HTLV-1 MTCT determinants have focused mainly on genetic host factors, 
immunological host factors, lactation duration and milk components. 
The genetic host factors that control HTLV-1 infection by breastfeeding have been investigated 
by Plancoulaine et al. [52], who began in the 1990s a large epidemiological study in endemic villages 
of French Guiana. The authors found a dominant major gene predisposing to HTLV-1 infection, in 
addition to the expected familial correlations due to the transmission routes (mother to child and 
spouse to spouse) [53]. Previous studies had shown that HLA (Human Leukocyte Antigen) genes 
distribution was different for ATLL or HAM/TSP patients compared to asymptomatic carriers (for 
example, see [54]), but the study by Plancoulaine et al. [53] indicated a genetic predisposition for 
HTLV-1 infection itself for 1.5% of the population, which concerned almost all infected children 
under 10 years of age, i.e., infected through breastfeeding. Further studies allowed mapping a major 
susceptibility locus for HTLV-1 infection during childhood to chromosome 6q27 [55]. 
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through the intestinal epithelium.
HTLV-1-infected lymphocytes, once they have crossed the mucus layer, could either pass through
the epithelium via M cells, or in-between enterocytes (paracellular passage), to reach the lamina
propria where potential targets of HTLV-1 infection, such as T lymphocytes (and/or dendritic cells
and B lymphocytes) are located. From in vitro studies [49], the infection of enterocytes or the epithelial
layer disruption seem to be excluded. Another possibility, suggested in the same study, could be viral
transcytosis throu h the entero te, with infection of underlying dendritic cells.
Interestingly, viral transcyt sis t rough enterocytes was observed only in the presence of HTLV-1
infected lymphocytes, and not in the case of purified virions. Such a mechanism of viral transcytosis
is reminiscent of previous work showing transcytosis of HIV across an epithelial barrier, without
infection of enterocytes, and subsequent infection of macrophages or CD4 lymphocytes located to
the basal side of the epithelium [51]. These in vitro results highlight one of the potential mechanisms
proposed for HTLV-1 passage, which are summarized in Figure 1.
4. Determinants of HTLV-1 MTCT
Studies o HTLV-1 MTCT determinants have focused mainly on genetic host factors,
immunological host factors, lactation duration and milk components.
The genetic host factors that co trol HTLV-1 infection by breastfeeding have been investigated
by Plancoulaine et al. [52], who began in the 1990s a large epidemiological study in endemic villages
of French Guiana. The authors found a dominant major gene predisposing to HTLV-1 infection, in
addition to the expected familial correlations due to the transmission routes (mother to child and
spouse to spouse) [53]. Previous studies had shown that HLA (Human Leukocyte Antigen) genes
distribution was different for ATLL or HAM/TSP patients compared to asymptomatic carriers (for
example, see [54]), but the study by Plancoulaine et al. [53] indicated a genetic predisposition for
HTLV-1 infection itself for 1.5% of the population, which concerned almost all infected children
under 10 years of age, i.e., infected through breastfeeding. Further studies allowed mapping a major
susceptibility locus for HTLV-1 infection during childhood to chromosome 6q27 [55].
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Concerning the immunological factors involved in HTLV-1 MTCT, the role of maternal
anti-HTLV-1 antibodies may appear controversial. Such studies have to take into account the duration
of breastfeeding, since the protective role of anti-HTLV-1 antibodies has been demonstrated in a rabbit
model of infection, where passive immunization was shown to prevent milk-borne transmission of
HTLV-1 to offspring [56]. Moreover, it has been shown in vitro that the addition of HTLV-1 serum
cord blood plasma is able to prevent the infection of human neonatal lymphocytes when co-cultured
with breast-milk cells of HTLV-1 carrier mothers [12]. However, it has been suggested that higher
anti-HTLV-1 antibodies titer in the serum of the mother, as well as the presence of anti-Tax antibodies, is
associated with a higher risk of children infection [11,52,57–59]. However, a high anti-HTLV-1 antibody
titer in the serum may be correlated with a high provirus load in PBMCs, which is a risk factor for
HTLV-1 MTCT [57]. In an analysis including the provirus load in maternal PBMCs, the presence of
anti-Tax antibodies and the anti-HTLV-1 titers, it was found that a higher maternal proviral load and a
higher anti-HTLV-1 antibody titer were independently associated with a higher risk of HTLV-1 MTCT,
whereas the presence of anti-Tax antibodies was not [60].
Another point to take into account concerns the other milk components that may influence
HTLV-1 MTCT transmission. As an example, it has been shown that lactoferrin, an iron-binding milk
glycoprotein, was able to enhance HTLV-1 replication, by transcriptional activation of HTLV-1 Long
Terminal Repeat (LTR), the viral promoter [61]. This effect on HTLV-1 infection seems to be specific
since lactoferrin did not show any effect on HIV-1 LTR, and was even able to inhibit HIV-1 infection,
probably by interfering with viral fusion and entry steps [61]. As an interesting example of “positive
feedback”, the same authors further demonstrated that lactoferrin expression was up-regulated during
HTLV-1 infection, probably in a paracrine manner involving Tax-induced NF-κB activation [62].
5. Ongoing Research on HTLV-1 MTCT and Perspectives
One of the major remaining questions on MTCT concerns the sites of primary passage/infection
of HTLV-1 in the digestive tract. The mechanisms of HTLV-1 infection after oral inoculation should be
addressed in vivo using a humanized mouse as a model of HTLV-1 infection [63–65], in complement to
the rabbit model. In particular, combination of histopathological studies and bioluminescence imaging
will allow determining the preferential sites of HTLV-1 entry (palatine tonsils, and/or gut). In parallel,
the use of transgenic, knock-out, and knock-in mice depleted for different cell types (M cells, dendritic
cells, and macrophages) will allow assessing the role of the different cell types in the first steps of
infection. These studies will also benefit from an in vitro approach, such as differentiation of M cells
from enterocytic cell lines, on compartmentalized culture devices, as already done to show the role of
these cells in virus transport across the epithelium [66]. Combination of in vivo/in vitro studies will
also allow delineating the role of factors such as milk components (e.g., lactoperoxidase), the proviral
load, and the antibody titer in HTLV-1 transport through the intestinal epithelium.
Another perspective concerns the comprehension of the role of breastfeeding duration on HTLV-1
MTCT. It seems rather clear that such a role corresponds to a combination of the cumulative viral
input, the changes over time in milk composition in infected cell types, maternal antibodies, and the
immune status and maturation of the neonate’s gut. It is known that neonatal life (as well as prenatal)
organizes and controls mucosal homeostasis through endogenous and exogenous factors that drive
the development and maturation of the intestinal immune system (for a review, see [67]). Recent
studies have shown the effects of intestinal microbiota in the development of the immune system and
intestinal architecture [68,69]. Gut microbiota could have an impact on HTLV-1 MTCT efficiency, as
reported for HIV-1 [70] or Mouse Mammary Tumor Virus [71], as well as the human milk microbiota,
which participate in the neonate’s gut microbiota constitution [72].
Altogether, these further studies could delineate new preventive strategies to counteract HTLV-1
MTCT, as well as provide new data on the general mechanisms of pathogenic agents in MTCT.
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